Skip to main content

Table 1 Comparison of baseline characteristics between the PF-ILD and non-PF-ILD groups among patients with fibrosing ILD

From: Progressive fibrosing interstitial lung disease: prevalence and clinical outcome

 

Total

PF-ILD

Non-PF-ILD

P-value

Number of patients

396

135

261

 

Age, years

58.1 ± 10.6

58.7 ± 10.1

57.9 ± 10.8

0.474

Male

158 (39.9)

58 (43.0)

100 (38.3)

0.388

BMI, kg/m2

23.8 ± 3.3

24.3 ± 3.6

23.6 ± 3.1

0.074

Ever-smokers

163 (41.2)

56 (41.5)

107 (41.0)

 > 0.999

ILD subtype

0.328

 iNSIP

76 (19.2)

20 (14.8)

56 (21.5)

 

 HP

52 (13.1)

29 (21.5)

23 (8.8)

 

 RA-ILD

168 (42.4)

58 (43.0)

110 (42.1)

 

 SSc-ILD

54 (13.6)

18 (13.3)

36 (13.8)

 

 SJS-ILD

46 (11.6)

10 (7.4)

36 (13.8)

 

PFT, % predicted

 FVC

73.3 ± 16.6

70.5 ± 16.5

74.7 ± 16.5

0.016

 DLCO

62.4 ± 18.0

60.0 ± 16.7

63.6 ± 18.6

0.059

 TLC

74.9 ± 14.8

71.7 ± 13.6

76.6 ± 15.1

0.002

HRCT pattern

0.750

 UIP-like pattern

181 (45.7)

60 (44.4)

121 (46.4)

 

 Non-UIP-like pattern

215 (54.3)

75 (55.6)

140 (53.6)

 

Treatment

0.078

 Steroid ± IMa

365 (92.2)

129 (95.6)

236 (90.4)

 

 No treatment

31 (7.8)

6 (4.4)

25 (9.6)

 
  1. Data are expressed as mean ± standard deviation or number (%), unless otherwise indicated. aMycophenolate mofetil (n = 151), azathioprine (n = 110)
  2. PF progressive fibrosing, ILD interstitial lung disease, BMI body mass index, iNSIP idiopathic nonspecific interstitial pneumonia, HP hypersensitivity pneumonitis, PFT pulmonary function test; FVC forced vital capacity, DLCO diffusing capacity of the lung for carbon monoxide, TLC total lung capacity, HRCT high-resolution computed tomography, UIP usual interstitial pneumonia, IM immunosuppressant